Calcinosis in juvenile dermatomyositis: Updates on pathogenesis and treatment

被引：11

作者：

Pinotti, Caitlan S. ^{[1
]}

Cannon, Laura ^{[2
]}

Dvergsten, Jeffrey A. ^{[1
]}

Wu, Eveline Y. ^{[2
,3
]}

机构：

[1] Duke Univ, Dept Pediat, Div Pediat Rheumatol, Durham, NC 27708 USA

[2] Univ N Carolina, Dept Pediat, Div Pediat Rheumatol, Chapel Hill, NC USA

[3] Univ North Carolina Chapel Hill, Dept Pediat, Div Pediat Allergy & Immunol, Chapel Hill, NC USA

来源：

FRONTIERS IN MEDICINE | 2023年 / 10卷

关键词：

juvenile dermatomyositis; calcinosis; myositis-specific antibody; pathogenesis; treatment; INFLAMMATORY MYOPATHIES; MYOSITIS; DISEASE; AUTOANTIBODIES; RECALCITRANT; FEATURES; CHILDREN;

D O I：

10.3389/fmed.2023.1155839

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Calcinosis, or the deposition of insoluble calcium salts in the skin, subcutaneous tissue, fascia, tendons, and muscles, is a feared complication of juvenile dermatomyositis. Calcinosis is estimated to affect up to 40% of patients with juvenile dermatomyositis and contributes to significant disease morbidity. Calcinosis can be challenging to treat, and the most effective treatment remains unknown because of a lack of comparative studies. We aim to review the literature published in the last 5 years to summarize updates on the pathogenesis and treatment of calcinosis in juvenile dermatomyositis and describe future areas for research.

引用

页数：7

共 57 条

[1] A child with severe juvenile dermatomyositis treated with ruxolitinib [J].

Aeschlimann, Florence A. ;

Fremond, Marie-Louise ;

Duffy, Darragh ;

Rice, Gillian I. ;

Charuel, Jean-Luc ;

Bondet, Vincent ;

Saire, Elsa ;

Neven, Benedicte ;

Bodemer, Christine ;

Balu, Laurent ;

Gitiaux, Cyril ;

Crow, Yanick J. ;

Bader-Meunier, Brigitte .

BRAIN, 2018, 141

[2] Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab [J].

Aggarwal, Rohit ;

Loganathan, Priyadarshini ;

Koontz, Diane ;

Qi, Zengbiao ;

Reed, Ann M. ;

Oddis, Chester V. .

RHEUMATOLOGY, 2017, 56 (02) :247-254

[3] Juvenile dermatomyositis-associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy [J].

Agud-Dios, Manuel ;

Arroyo-Andres, Jorge ;

Rubio-Muniz, Carmen ;

Zarco-Olivo, Carlos ;

Calleja-Algarra, Alba ;

de Inocencio, Jaime ;

Palencia Perez, Sara Isabel .

DERMATOLOGIC THERAPY, 2022, 35 (12)

[4]

Alhemairi M., 2017, OPEN J RHEUMATOL AUT, V7, P16, DOI [10.4236/ojra.2017.71002, DOI 10.4236/OJRA.2017.71002]

[5] Juvenile dermatomyositis: a tertiary center experience [J].

Barut, Kenan ;

Aydin, Pinar Ozge Avar ;

Adrovic, Amra ;

Sahin, Sezgin ;

Kasapcopur, Ozgur .

CLINICAL RHEUMATOLOGY, 2017, 36 (02) :361-366

[6] Complete and sustained resolution of calcinosis universalis in a juvenile dermatomyositis case with mycophenolate mofetil [J].

Cakan, Mustafa ;

Karadag, Serife Gul ;

Ayaz, Nuray Aktay .

TURKISH JOURNAL OF PEDIATRICS, 2019, 61 (05) :771-775

[7] Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients [J].

Campanilho-Marques, Raquel ;

Deakin, Claire T. ;

Simou, Stefania ;

Papadopoulou, Charalampia ;

Wedderburn, Lucy R. ;

Pilkington, Clarissa A. .

ARTHRITIS RESEARCH & THERAPY, 2020, 22 (01)

[8] Calcinosis in dermatomyositis: Origins and possible therapeutic avenues [J].

Davuluri, Srijana ;

Duvvuri, Bhargavi ;

Lood, Christian ;

Faghihi-Kashani, Sara ;

Chung, Lorinda .

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2022, 36 (02)

[9]

Deguzman M., 2017, ARTHRITIS RHEUMATOL, V69

[10]

Duvvuri B., 2019, ARTH RHEUMATOL, V71, P4838

← 1 2 3 4 5 6 →